title: [The new oral anticoagulants in special populations].
abstract: The new oral anticoagulants are now a reality and are available to clinicians. Although a large number of patients have been included in the many clinical trials of these drugs, there is one population that is always underrepresented - called special populations - such as those aged more than 75 years old, the obese, and patients with renal impairment. This review aims to analyze differences in the efficacy and safety in these special populations recruited in the various trials.
authors.affiliation: Servicio de Medicina Interna, Hospital Universitario Dr. Josep Trueta, Girona, España. fgarciabragado.girona.ics@gencat.cat
authors.forename: Ferran García-Bragado
authors.initials: FG
authors.lastname: Dalmau
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D000925:Anticoagulants / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D000075202:Contraindications; D000069604:Dabigatran; D004617:Embolism / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D009765:Obesity / Q000150:complications*; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000150:complications*; D000069552:Rivaroxaban; D020521:Stroke / Q000150:complications / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use; D013927:Thrombosis / Q000150:complications / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran